Participated · Series B · Aug 2026

Mariana Minerals combines proprietary software and capital project execution to build and operate mines and refineries for critical minerals. Its MarianaOS platform integrates CapitalProjectOS, PlantOS and MineOS into a single AI and machine learning stack intended to compress multi-year project execution timelines and reduce commissioning time. The company operates active projects including Copper One, which is ramping toward 50,000 metric tons of refined copper per year, and Lithium One, a GWh-scale facility targeting commercial lithium production from oil & gas produced water in the first half of 2027. Mariana has raised roughly $400 million of parent and project capital to date, including the $310 million Series B. The company plans to scale to 10 commercial-scale projects in 10 years, using data from each project to improve its software and lower costs for subsequent builds.

Led · Series B · Jul 2026

Flex positions itself as a private bank for high-net-worth and middle-market business owners, providing multi-currency accounts, stablecoin payment systems and wallets, institutional USD accounts, private credit, business cards across entities, and an AI finance agent called Beacon. The company has launched Flex Global, a stablecoin-powered banking service available in more than 100 countries, with multi-currency accounts in 76 countries supporting 32 currencies. Flex reports strong growth metrics: annualised total payment volume exceeding $10 billion, annualised revenue now in nine figures after tripling since December, and customers using an average of four or more products. Its largest client categories by count are construction, wholesale, and multinational businesses, and it targets an estimated 350,000 high-net-worth business owners in the U.S. and about 3 million worldwide. Flex plans to expand into business finance, personal finance, payments, private credit, and ERP, and to roughly double headcount from ~110 to over 200 within the year.

Participated · Equity · Oct 2025

1Password provides an Extended Access Management platform that secures credentials and identities for both individual users and more than 175,000 business customers, including over two-thirds of the Forbes AI 50. The service delivers password management, secrets automation, and broader identity security capabilities to millions of users worldwide. In 2025 the company expanded its roadmap by launching Agentic AI Security to help enterprises govern AI automation and by releasing an MCP server that adds SaaS visibility to AWS-native workflows. 1Password also partnered with Perplexity’s Comet browser to supply safer AI browsing and introduced Agentic Autofill with Browserbase to give AI agents a secure credential layer for real-time decisions. These product moves signal a deeper push into AI-centric security use cases and cloud integrations. The company’s scale and continued platform expansion underpin a reported $6.8 billion valuation following its latest secondary transaction.

Led · Equity · Sep 2025

Filevine is a Salt Lake City–based legal-tech company that has spent more than a decade building a Legal Operating Intelligence System that embeds AI into lawyers’ daily workflows. The cloud platform consolidates emails, texts, documents, deposition videos, billing, compliance data and more, giving legal teams a single system of record with real-time intelligence. It is used by nearly 6,000 customers and 100,000 legal professionals, who collectively upload more than 20 million pages of documents every day. Filevine reports best-in-class customer metrics, including over 96 % gross retention for its core platform and Net Dollar Retention above 120 %. Recent diligence also showed about 130 % year-over-year AI revenue growth and more than 20 % week-over-week growth for its cross-platform AI chat tool. With fresh capital, the company plans to scale product development, deepen AI capabilities, expand go-to-market efforts and grow its enterprise and government customer base.

Participated · Equity · May 2018

RenovoRx is a clinical‑stage biopharmaceutical company developing RenovoGem, an oncology drug‑device combination delivered via its proprietary TAMP platform. Its lead program is the pivotal TIGeR‑PaC Phase III study in locally advanced pancreatic cancer, with a primary endpoint of a 6‑month overall survival benefit and secondary endpoints assessing reduced side effects versus standard intravenous chemotherapy. The first interim analysis (26th event) was completed in March 2023 with the Data Monitoring Committee recommending continuation; a second interim analysis is expected at the 52nd event in late 2024. Data from the program have been presented at major oncology meetings, and the company plans a second late‑stage CouGar Phase III study in bile duct cancer. RenovoRx has identified additional potential indications (NSCLC, uterine tumors, glioblastoma, sarcoma) but will require more funding to pursue them. The company says the recent financing bolsters its balance sheet to advance late‑stage programs and reach near‑term clinical milestones. RenovoRx develops the RenovoCath, a dual-balloon infusion catheter designed to isolate blood flow and deliver chemotherapy directly to pancreatic tumors without identifying local blood vessels. The company received FDA clearance for RenovoCath in 2014, a CE Mark in 2015, and expanded FDA labeling in 2017. Based on early feasibility data, the targeted intra-arterial approach suggested an improved survival benefit versus historical controls for locally advanced pancreatic cancer. The FDA granted RenovoCath an Orphan Drug Designation and approved an Investigational New Drug (IND) application enabling the company to proceed directly to a pivotal Phase III study. Enrollment has begun in a randomized Phase III trial comparing intra-arterial chemotherapy via RenovoCath to systemic chemotherapy in ~300 patients at up to 20 U.S. sites, with overall survival as the primary endpoint and safety and quality of life as secondary endpoints. The announced financing will be used to support ongoing product development and these clinical trials. RenovoRx, founded in 2009 and based in San Jose, California, develops novel catheter technologies to deliver fluids to the peripheral vascular system. Its system enables direct, localized delivery of fluids, including radiopaque material and therapeutic agents, to selected sites. The company is led by CEO Marta Gaia Zanchi, COO/CTO Kamran Najmabadi, and CMO Ramtin Agah. In January 2014 RenovoRx closed a $1.15M Series B financing to advance its program. Management says the proceeds will be used to support important milestones and to meet clinical need for its system in 2014. The financing reflects continued investor interest as the company progresses toward clinical objectives.